2017 Pediatric Rheumatology Symposium

May 17-20, 2017. Houston, Texas.

View by Number View by Title View Sessions

View by Date

Abstract Number: 31

Predicting therapy response to IL-1 blockade in systemic JIA: a biomarker search
Abstract Number: 32

High Mobility Group Box 1 Protein in Children with Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis
Abstract Number: 33

An extracellular ionic milieu renders human granulocytic S100A12 into a pro-inflammatory TLR4-binding alarmin
Abstract Number: 34

The SLCO1B1 *14 Allele is Associated with Poor Response to Subcutaneous Methotrexate in Patients with Juvenile Idiopathic Arthritis
Abstract Number: 35

Kv1.3 Expression on Urinary Leukocytes in Lupus Nephritis: Potential for Targeted Immunotherapy
Abstract Number: 36

The Association of Obesity with Pediatric Psoriatic Arthritis
Abstract Number: 37

Increased Involvement of Teenagers with Juvenile Idiopathic Arthritis in Treatment Decisions Using Medication Choice Cards: Preliminary Report from a Case-Control Study
Abstract Number: 38

Knowledge Translation in Juvenile Idiopathic Arthritis Research in Canada: A Focus on Pediatric Rheumatologists and Allied Health Professionals
Abstract Number: 39

Rheumapalooza: A rheumatology curriculum in evolution
Abstract Number: 40

Perspectives of young people with Juvenile Idiopathic Arthritis, their caregivers, and health care providers on transition to adult care: Informing development of a transition toolkit
Abstract Number: 41

Identification of Optimal Subcutaneous Doses of Tocilizumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis
Abstract Number: 42

Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age With Systemic Juvenile Idiopathic Arthritis
Abstract Number: 43

Tocilizumab Use in Pediatrics With Systemic Juvenile Idiopathic Arthritis: Single Center Data
Abstract Number: 44

Long-term Efficacy and Safety of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results From a Phase III Extension Study
Abstract Number: 45

Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease